Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHMSA Gazyva Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentHawaii Medical Service Association (HMSA)Policy 01-2026

    Gazyva (obinutuzumab) Coverage for Active Lupus Nephritis

    Customize your policy alerts

    Sign up for Hawaii Medical Service Association (HMSA) Policy 01-2026 alerts

    Get alerted when Policy 01-2026 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs HMSA coverage and prior authorization for Gazyva (obinutuzumab) for adults with active lupus nephritis receiving standard therapy across HMO, PPO, and QUEST lines of business.

    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyGazyva (obinutuzumab) Coverage for Active Lupus Nephritis
    Policy CodePolicy 01-2026
    Change TypeNo material change
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionPrior authorization is required; refer to the HMSA medical specialty drug policy website for the fax form.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsStandard authorization duration
    2Initial coverage criteria
    RequiredPrior authorization
    3Standard therapies listed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Initial therapy — active lupus nephritis

    Authorization of 12 months may be granted for treatment of active lupus nephritis when both criteria are met.

    Initial therapy

    • Kidney biopsy confirmation: Prior to initiating therapy, lupus nephritis was confirmed on kidney biopsy.

      Kidney biopsy is not required if contraindicated.

    • Standard therapy regimen: The member is receiving a standard therapy regimen, such as cyclophosphamide, mycophenolate mofetil, azathioprine, or glucocorticoids.

    Continuation therapy — lupus nephritis

    Authorization of 12 months may be granted for reauthorization when the member was previously authorized by HMSA/CVS for Bimzelx and achieves or maintains a positive clinical response.

    Continuation therapy

    • Previous authorization: The member was previously authorized by HMSA/CVS for Bimzelx.
    • Positive clinical response: The member achieves or maintains a positive clinical response, evidenced by low disease activity or improvement in signs and symptoms of the condition.

    Provider Actions and Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Gazyva (obinutuzumab). Refer to the HMSA medical specialty drug policy website for the required fax form.

    Documentation Required

    Clinical Documentation Required

    Submit medical records supporting the request. Initial requests require documentation of the diagnosis and kidney biopsy findings; continuation requests require documentation of disease stability or improvement.

    • Initial requests: medical records such as chart notes and laboratory reports documenting a kidney biopsy supporting the diagnosis.
    • Continuation requests: medical records such as chart notes and laboratory reports documenting disease stability or improvement.
    Denial Risk

    Failure to Meet Coverage Criteria

    Coverage may be denied when the requested use is not a covered FDA-approved or compendial indication, when any approval criterion is unmet, or when an exclusion or other applicable policy requirement applies.

    • For active lupus nephritis, authorization requires kidney-biopsy confirmation before therapy unless contraindicated and concurrent standard therapy, such as cyclophosphamide, mycophenolate mofetil, azathioprine, or glucocorticoids.
    • Coverage is provided only when all approval criteria are met and the member has no exclusion to the prescribed therapy.
    • Dosing limits may apply in accordance with FDA-approved labeling, accepted compendia, or evidence-based practice guidelines.

    Policy Background

    Gazyva (obinutuzumab) is covered for adult patients with active lupus nephritis who are receiving standard therapy, provided the applicable approval criteria are met and no exclusions apply. Initial authorization may be granted for 12 months when lupus nephritis was confirmed by kidney biopsy, unless biopsy is contraindicated, and the member is receiving a standard therapy regimen. Reauthorization may also be granted for 12 months when the member was previously authorized by HMSA/CVS for Bimzelx and has achieved or maintained a positive clinical response, such as low disease activity or improvement in signs and symptoms. Prior authorization is required.

    Initial Therapy for Active Lupus Nephritis

    Initial therapy for active lupus nephritis

    Authorization of 12 months may be granted for treatment of active lupus nephritis when both criteria are met.

    Initial therapy

    • Kidney biopsy confirmation: Prior to initiating therapy, lupus nephritis was confirmed on kidney biopsy.

      Unless contraindicated.

    • Standard therapy regimen: The member is receiving a standard therapy regimen, such as cyclophosphamide, mycophenolate mofetil, azathioprine, or glucocorticoids.

    Continuation Therapy

    Continuation therapy

    Authorization of 12 months may be granted for continuation therapy when the member was previously authorized by HMSA/CVS for Bimzelx and achieves or maintains a positive clinical response.

    • Previous authorization: The member was previously authorized by HMSA/CVS for Bimzelx.
    • Clinical response or maintenance: The member achieves or maintains a positive clinical response, evidenced by low disease activity or improvement in signs and symptoms of the condition.
    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyGazyva (obinutuzumab) Coverage for Active Lupus Nephritis
    Policy CodePolicy 01-2026
    Change TypeNo material change
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionPrior authorization is required; refer to the HMSA medical specialty drug policy website for the fax form.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and RequirementsPolicy BackgroundInitial Therapy for Active Lupus NephritisContinuation Therapy